glp-1 companies list The Peptide Paradox: Why Miracle Drugs Might Be Making Us Weaker The Next Big Weight Loss

De Pablo-Fernandez E, Goldacre R, Pakpoor J, Noyce AJ, Warner TT

Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk

The patient must: Be age 18 or older Have eligible Medicare Part D coverage Be prescribed treatment specifically for weight reduction and maintenance Participate in ongoing nutrition and physical activity intervention Not have already received a GLP-1 through their Part D plan Not be seeking coverage for another Part D-coverable indication, such as type 2 diabetes, moderate-to-severe obstructive sleep apnea, MASH, or cardiovascular risk reduction The patient must also have met one of these criteria when GLP-1 therapy was originally started: BMI 35 BMI 30 plus HFpEF, uncontrolled hypertension despite 2 medications, or CKD stage 3a+ BMI 27 plus prediabetes, prior MI, prior stroke, or symptomatic peripheral artery disease Important: Eligibility is based on BMI at treatment initiation, not necessarily the patients current BMI

[DOI] [PMC free article] [PubMed] [Google Scholar] 37.Obesity Medications: What Does the Future Hold

Nausea is the most common, particularly during dose escalation

February 26, 2024